



Biotech Daily

Friday January 2, 2009

SPECIAL SUMMER EDITION

The Biotech Daily Top 40 Index (BDI-40) climbed three percent in the month of December 2008, compared to a 0.56 percent fall in the S&P ASX 200 index. Eighteen biotechnology stocks climbed, five were unchanged and 17 fell in December.

The BDI-20 was up 6.9 percent for the month only in part due to the promotion of Universal Biosensors at the expense of Tyrian Diagnostics the previous month.

Polartech's 90.9 percent increase in market capitalization to \$42 million pushed the Second 20 and the Top 40 up by \$20 million, followed by Heartware's \$55 million or 42.3 percent increase to \$185 million. Universal Biosensors was up 34.8 percent followed by Benitec (22.2%), Impedimed (15.4%), Mesoblast (14.2%) and Clinuvel (14.1%)


Neuren led the falls, down 82.4 percent to a market capitalization of \$3 million on the news that Glypromate equaled placebo in its phase III trial for neuro-protection in cardiac surgery. Tyrian fell \$4 million or 36.4 percent to \$7 million, followed down by Bone (32.0%), Avexa (31.1%), Living Cell (27.3%), Cathrx (25%) and Sunshine Heart (25%).

The three Big Caps: Cochlear, CSL and Resmed (which are not included in the BDI-40) fell a further 2.8 percent in the month of December and were five percent lower for the year to December 31, 2008.

The S&P ASX 200 fell 41.3 percent for the year to December 31, 2008 compared to the BDI-40 down 53.7 percent, the BDI-20 falling 51.6 percent and the Second 20 down 59.8 percent.

Neuren will be replaced in the BDI-20 by Impedimed, with Genera Biosystems promoted to the Second 20.

Biotech Daily Top 40 (\$m) v S&P ASX 200



BIOTECH DAILY TOP 40 WITH MARKET CAP

Big Caps \$Am	Jan 2, 2009	Dec 1, 2008	Nov 3, 2008
Cochlear	3,101	3,094	3,189
CSL	20,321	20,919	21,936
Resmed	3,887	4,072	3,746
Top 20			
Acrux	76	74	105
Alchemia	26	23	27
Arana	190	186	182
Avexa	31	45	49
Bionomics	53	55	61
Biota	58	64	59
Cellestis	168	180	193
Chemgenex	111	99	110
Cytopia	15	14	13
Heartware	185	130	161
Living Cell	24	33	43
Mesoblast	121	106	109
Neuren	3	17	15
Novogen	70	79	98
Peplin	59	47	58
Pharmaxis	235	233	292
Phosphagenics	51	50	43
Sirtex	94	106	118
Starpharma	35	36	52
Universal Biosensors	93	69	74
Second 20			
Antisense	20	22	26
Benitec	11	9	15
Bone Medical	17	25	25
Cathrx	21	28	28
Circadian	26	25	31
Clinuvel	73	64	76
Genetic Tech	19	17	14
Impedimed	60	52	54
Labtech	12	12	16
Optiscan	7	7	7
Phylogica	7	7	9
Polartech	42	22	19
Prana	64	61	73
Progen	47	47	40
Psivida	13	15	16
Stem Cell Sciences	5	5	6
Sunshine Heart	12	16	18
Tyrian	7	11	15
Ventracor	20	23	23
Viralytics	11	14	14

* Biotech Daily editor, David Langsam, owns shares in Alchemia, Biota, Chemgenex, Cytopia and Stem Cell Sciences as well as non-biotechnology stocks. These are liable to change at any time.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
 email: editor@biotechdaily.com.au www.biotechdaily.com.au